News | July 31, 2025
Bristol Myers Squibb and Bain Capital launch biotech company NewCo
NewCo’s pipeline includes five investigational medicines
NewCo’s pipeline includes five investigational medicines
For patients with resectable early-stage gastric and gastroesophageal junction cancers
This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Subscribe To Our Newsletter & Stay Updated
